Results of the aphereses
| Group/patient no. . | Post-cyclophosphamide harvests . | Post-cytabarine harvests . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis . | Probe . | No. of aphereses (day of 1st apheresis) . | CD34+ (×106/kg) . | Results of PCR analysis . | No. of aphereses (day of 1st apheresis) . | CD34+ (×105/kg) . | Results of PCR analysis . | CD34+ (×106/kg) after ex vivo purging . | PCR analysis after ex vivo purging . | |
| HDS (n = 10) | ||||||||||
| 1 | MCL | bcl1 | 2 (13) | 24.3 | + | 2 (12) | 24.9 | − | ||
| 2 | MCL | bcl1 | 1 (13) | 28.8 | + | 2 (14) | 29.9 | + | 8.6 | − |
| 3 | Foll | bcl2 | 1 (12) | 2.4 | + | 2 (12) | 45 | + | 12.2 | − |
| 4 | Foll | bcl2 | 1 (13) | 3 | + | 2 (12) | 12.9 | + | 7.6 | − |
| 5 | Foll | bcl2 | 1 (16) | 5.7 | − | 2 (14) | 20.4 | − | ||
| 6 | Foll | bcl2 | 1 (13) | 8.3 | + | 3 (13) | 11.8 | − | ||
| 7 | Foll | bcl2 | 1 (12) | 17 | + | 1 (12) | 17.8 | + | 5.3 | + |
| 8 | Foll | bcl2 | 1 (13) | 14.5 | + | 2 (13) | 33.6 | + | 9.2 | − |
| 9 | MCL | bcl1 | 1 (12) | 16.1 | + | 1 (13) | 37 | − | ||
| 10 | Foll | IgH | ND | 1 (17) | 3.2 | + | ||||
| R-HDS (n = 15) | ||||||||||
| 11 | Foll | bcl2 | 1 (13) | 15 | + | 1 (13) | 65.2 | − | ||
| 12 | Foll | IgH | 1 (17) | 14.8 | − | ND | ||||
| 13 | Foll | bcl2 | 1 (17) | 2.3 | + | 1 (14) | 17.5 | − | ||
| 14 | MCL | IgH | 2 (15) | 13 | − | ND | ||||
| 15 | Foll | bcl2 | 1 (15) | 33.2 | − | ND | ||||
| 16 | Foll | IgH | 1 (15) | 21.6 | − | ND | ||||
| 17 | Foll | bcl2 | 1 (33) | 4.2 | + | 2 (12) | 23.6 | − | ||
| 18 | MCL | bcl1 | 1 (15) | 17.6 | + | 2 (12) | 26.6 | − | ||
| 19 | MCL | bcl1 | 1 (10) | 24.4 | + | 1 (10) | 32.4 | − | ||
| 20 | MALT | IgH | 1 (17) | 2.6 | + | 1 (13) | 14 | + | ND | |
| 21 | MCL | IgH | 1 (14) | 12 | + | 1 (13) | 63.6 | − | ||
| 22 | MCL | IgH | 1 (14) | 8 | + | 2 (13) | 15 | − | ||
| 23 | MCL | IgH | 1 (17) | 7 | + | 1 (13) | 28 | − | ||
| 24 | MCL | bcl1 | 1 (13) | 5.8 | + | 2 (12) | 16 | − | ||
| 25 | Foll | IgH | 2 (15) | 7.8 | − | 1 (11) | 6.3 | − | ||
| Group/patient no. . | Post-cyclophosphamide harvests . | Post-cytabarine harvests . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis . | Probe . | No. of aphereses (day of 1st apheresis) . | CD34+ (×106/kg) . | Results of PCR analysis . | No. of aphereses (day of 1st apheresis) . | CD34+ (×105/kg) . | Results of PCR analysis . | CD34+ (×106/kg) after ex vivo purging . | PCR analysis after ex vivo purging . | |
| HDS (n = 10) | ||||||||||
| 1 | MCL | bcl1 | 2 (13) | 24.3 | + | 2 (12) | 24.9 | − | ||
| 2 | MCL | bcl1 | 1 (13) | 28.8 | + | 2 (14) | 29.9 | + | 8.6 | − |
| 3 | Foll | bcl2 | 1 (12) | 2.4 | + | 2 (12) | 45 | + | 12.2 | − |
| 4 | Foll | bcl2 | 1 (13) | 3 | + | 2 (12) | 12.9 | + | 7.6 | − |
| 5 | Foll | bcl2 | 1 (16) | 5.7 | − | 2 (14) | 20.4 | − | ||
| 6 | Foll | bcl2 | 1 (13) | 8.3 | + | 3 (13) | 11.8 | − | ||
| 7 | Foll | bcl2 | 1 (12) | 17 | + | 1 (12) | 17.8 | + | 5.3 | + |
| 8 | Foll | bcl2 | 1 (13) | 14.5 | + | 2 (13) | 33.6 | + | 9.2 | − |
| 9 | MCL | bcl1 | 1 (12) | 16.1 | + | 1 (13) | 37 | − | ||
| 10 | Foll | IgH | ND | 1 (17) | 3.2 | + | ||||
| R-HDS (n = 15) | ||||||||||
| 11 | Foll | bcl2 | 1 (13) | 15 | + | 1 (13) | 65.2 | − | ||
| 12 | Foll | IgH | 1 (17) | 14.8 | − | ND | ||||
| 13 | Foll | bcl2 | 1 (17) | 2.3 | + | 1 (14) | 17.5 | − | ||
| 14 | MCL | IgH | 2 (15) | 13 | − | ND | ||||
| 15 | Foll | bcl2 | 1 (15) | 33.2 | − | ND | ||||
| 16 | Foll | IgH | 1 (15) | 21.6 | − | ND | ||||
| 17 | Foll | bcl2 | 1 (33) | 4.2 | + | 2 (12) | 23.6 | − | ||
| 18 | MCL | bcl1 | 1 (15) | 17.6 | + | 2 (12) | 26.6 | − | ||
| 19 | MCL | bcl1 | 1 (10) | 24.4 | + | 1 (10) | 32.4 | − | ||
| 20 | MALT | IgH | 1 (17) | 2.6 | + | 1 (13) | 14 | + | ND | |
| 21 | MCL | IgH | 1 (14) | 12 | + | 1 (13) | 63.6 | − | ||
| 22 | MCL | IgH | 1 (14) | 8 | + | 2 (13) | 15 | − | ||
| 23 | MCL | IgH | 1 (17) | 7 | + | 1 (13) | 28 | − | ||
| 24 | MCL | bcl1 | 1 (13) | 5.8 | + | 2 (12) | 16 | − | ||
| 25 | Foll | IgH | 2 (15) | 7.8 | − | 1 (11) | 6.3 | − | ||
PCR indicates polymerase chain reaction; HDS, high-dose sequential therapy; MCL, mantle cell lymphoma; Foll, follicular lymphoma; ND, not done because of failure of mobilization after high-dose cyclophosphamide; R-HDS, rituximab and high-dose sequential therapy; and MALT, marginal-zone lymphoma (mucosa-associated lymphoid tissue type).